
Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …
In a new government initiative doctors who consistently fail to diagnose signs of cancer could be publically named on an …

The annual American Society of Clinical Oncology (ASCO) meeting has long been one of the most important events on the …
Novartis is to grow its pharma business by focussing on five key areas and predicts that it will have 14 …

Novartis has hired Merck’s president of Europe and Canada Bruno Strigini to be its president of oncology. The role was …
GlaxoSmithKline has signed a deal to develop and commercialise biotech firm Adaptimmune’s lead clinical cancer programme with T-cell receptors (TCRs), …

Bristol-Myers Squibb has partnered with CytomX Therapeutics to discover and develop new immuno-oncology candidates using the latter’s Probody Platform technology. …

Roche’s most advanced experimental cancer immunotherapy has had impressive results in a small Phase I trial, reducing tumour size in …

MedImmune, the global biologics R&D arm of AstraZeneca, is to put one of its oncology immunotherapies into development in combination …

GlaxoSmithKline’s melanoma drug Mekinist is virtually nailed on to be given approval in the European Union following a positive opinion …


In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …

Contract manufacturing organisation Cobra Biologics has signed a deal with specialist oncology biopharma firm BioCancell to manufacture an investigational cancer …

AbbVie is expanding its manufacturing operation into Asia for the first time with a $320 million investment in a new …

AbbVie has begun a Phase III trial of its investigational compound veliparib in women with early-stage, triple-negative breast cancer. This …